Cancer clinical trials in the region Occitanie

385 currently recruiting clinical trials
Region Occitanie
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Ruxolitinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Momelotinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras de monothérapie par nuvisertib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Breast cancer #NCT05386108 #2024-512878-98-00
Phase 2
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Stemline Therapeutics, Inc.
Phase 1 / Phase 2 Cervical / Vulvar / Vaginal cancer #NCT06923761 #2023-504845-30-00
Module 2 (Parties C et D) Cohorte 1 Cancer du col
Required histologic types
Cervical cancer
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Liver and bile duct cancer #NCT06923761 #2023-504845-30-00
Module 2 (Parties C et D) Cohorte 2 carcinome hépatocellulaire
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04585750 #2023-504251-27-00
Phase 2 cohorte de patientes atteintes d'un cancer de l'ovaire
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Lung cancer #NCT04585750 #2023-504251-27-00
Phase 2 cohorte de patients atteints de cancer du poumon
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Breast cancer #NCT04585750 #2023-504251-27-00
Phase 2 cohorte de cancer du sein
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc